{"id":"https://openalex.org/W4394428893","doi":"https://doi.org/10.6084/m9.figshare.19885937","title":"Healthcare resource utilization and costs among patients with psoriasis treated with ixekizumab or adalimumab over 2 years of follow-up in real-world settings","display_name":"Healthcare resource utilization and costs among patients with psoriasis treated with ixekizumab or adalimumab over 2 years of follow-up in real-world settings","publication_year":2022,"publication_date":"2022-01-01","ids":{"openalex":"https://openalex.org/W4394428893","doi":"https://doi.org/10.6084/m9.figshare.19885937"},"language":"en","primary_location":{"id":"pmh:oai:figshare.com:article/19885937","doi":null,"is_oa":true,"landing_page_url":"https://figshare.com/articles/dataset/Healthcare_resource_utilization_and_costs_among_patients_with_psoriasis_treated_with_ixekizumab_or_adalimumab_over_two_years_of_follow-up_in_real-world_settings/19885937","pdf_url":null,"source":{"id":"https://openalex.org/S4377196282","display_name":"Figshare","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I4210132348","host_organization_name":"Figshare (United Kingdom)","host_organization_lineage":["https://openalex.org/I4210132348"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"","raw_type":"Dataset"},"volume":null,"type":"dataset","is_traditional":false,"indexed_in":["datacite"],"open_access":{"is_oa":true,"oa_status":"green","oa_url":"https://figshare.com/articles/dataset/Healthcare_resource_utilization_and_costs_among_patients_with_psoriasis_treated_with_ixekizumab_or_adalimumab_over_two_years_of_follow-up_in_real-world_settings/19885937","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5080237247","display_name":"Andrew Blauvelt","orcid":"https://orcid.org/0000-0002-2633-985X","observed_orcids":["https://orcid.org/0000-0002-2633-985X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Blauvelt, Andrew","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103078522","display_name":"Nianwen Shi","orcid":"https://orcid.org/0000-0002-0596-7566","observed_orcids":["https://orcid.org/0000-0002-0596-7566"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Shi, Nianwen","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5060348893","display_name":"Mwangi J. Murage","orcid":"https://orcid.org/0000-0003-2769-3188","observed_orcids":["https://orcid.org/0000-0003-2769-3188"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Murage, Mwangi J.","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110795734","display_name":"Scott A. Kern","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Kern, Scott A.","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5053940783","display_name":"Najwa Somani","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Somani, Najwa","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5001431413","display_name":"Russel Thomas Burge","orcid":"https://orcid.org/0000-0001-7907-6400","observed_orcids":["https://orcid.org/0000-0001-7907-6400"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Burge, Russel","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5068529059","display_name":"Terri Ridenour","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Ridenour, Terri L.","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110495136","display_name":"Carolyn Ritterson Lew","orcid":"https://orcid.org/0000-0003-1115-0672","observed_orcids":["https://orcid.org/0000-0003-1115-0672"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Lew, Carolyn R.","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5083473676","display_name":"Nicole M. Zimmerman","orcid":"https://orcid.org/0000-0001-5819-7844","observed_orcids":["https://orcid.org/0000-0001-5819-7844"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Zimmerman, Nicole M.","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5057319160","display_name":"Baojin Zhu","orcid":"https://orcid.org/0000-0003-4462-1856","observed_orcids":["https://orcid.org/0000-0003-4462-1856"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Zhu, Baojin","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10469","display_name":"Psoriasis: Treatment and Pathogenesis","score":0.9940999746322632,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10469","display_name":"Psoriasis: Treatment and Pathogenesis","score":0.9940999746322632,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10804","display_name":"Health Systems, Economic Evaluations, Quality of Life","score":0.0032999999821186066,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},{"id":"https://openalex.org/T11092","display_name":"Spondyloarthritis Studies and Treatments","score":0.0005000000237487257,"subfield":{"id":"https://openalex.org/subfields/2745","display_name":"Rheumatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/psoriasis","display_name":"psoriasis","score":0.9990000128746033},{"id":"https://openalex.org/keywords/ixekizumab","display_name":"ixekizumab","score":1.0},{"id":"https://openalex.org/keywords/adalimumab","display_name":"adalimumab","score":1.0},{"id":"https://openalex.org/keywords/healthcare-resource-utilization","display_name":"healthcare resource utilization","score":0.9779999852180481},{"id":"https://openalex.org/keywords/health-care-costs","display_name":"health care costs","score":0.9850000143051147},{"id":"https://openalex.org/keywords/biological-therapy","display_name":"biologic therapy","score":0.9430000185966492},{"id":"https://openalex.org/keywords/hospitalization","display_name":"hospitalization","score":0.7179999947547913},{"id":"https://openalex.org/keywords/length-of-hospital-stay","display_name":"length of hospital stay","score":0.8889999985694885},{"id":"https://openalex.org/keywords/treatment-adherence","display_name":"medication adherence","score":0.9350000023841858},{"id":"https://openalex.org/keywords/real-world-evidence","display_name":"real-world evidence","score":0.6380000114440918}],"concepts":[{"id":"https://openalex.org/C2779745271","wikidata":"https://www.wikidata.org/wiki/Q13574436","display_name":"Ixekizumab","level":5,"score":0.95366370677948},{"id":"https://openalex.org/C2780132546","wikidata":"https://www.wikidata.org/wiki/Q348260","display_name":"Adalimumab","level":3,"score":0.757860541343689},{"id":"https://openalex.org/C2780564577","wikidata":"https://www.wikidata.org/wiki/Q179945","display_name":"Psoriasis","level":2,"score":0.7274453639984131},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.5476535558700562},{"id":"https://openalex.org/C160735492","wikidata":"https://www.wikidata.org/wiki/Q31207","display_name":"Health care","level":2,"score":0.5217465162277222},{"id":"https://openalex.org/C144133560","wikidata":"https://www.wikidata.org/wiki/Q4830453","display_name":"Business","level":0,"score":0.4173443019390106},{"id":"https://openalex.org/C16005928","wikidata":"https://www.wikidata.org/wiki/Q171171","display_name":"Dermatology","level":1,"score":0.2618981599807739},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.17796164751052856},{"id":"https://openalex.org/C2776260265","wikidata":"https://www.wikidata.org/wiki/Q511097","display_name":"Psoriatic arthritis","level":3,"score":0.10568135976791382},{"id":"https://openalex.org/C2779134260","wikidata":"https://www.wikidata.org/wiki/Q12136","display_name":"Disease","level":2,"score":0.09708932042121887},{"id":"https://openalex.org/C50522688","wikidata":"https://www.wikidata.org/wiki/Q189833","display_name":"Economic growth","level":1,"score":0.09620946645736694},{"id":"https://openalex.org/C162324750","wikidata":"https://www.wikidata.org/wiki/Q8134","display_name":"Economics","level":0,"score":0.09557285904884338},{"id":"https://openalex.org/C2779786854","wikidata":"https://www.wikidata.org/wiki/Q7444755","display_name":"Secukinumab","level":4,"score":0.09515681862831116}],"mesh":[],"locations_count":4,"locations":[{"id":"pmh:oai:figshare.com:article/19885937","doi":null,"is_oa":true,"landing_page_url":"https://figshare.com/articles/dataset/Healthcare_resource_utilization_and_costs_among_patients_with_psoriasis_treated_with_ixekizumab_or_adalimumab_over_two_years_of_follow-up_in_real-world_settings/19885937","pdf_url":null,"source":{"id":"https://openalex.org/S4377196282","display_name":"Figshare","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I4210132348","host_organization_name":"Figshare (United Kingdom)","host_organization_lineage":["https://openalex.org/I4210132348"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"","raw_type":"Dataset"},{"id":"doi:10.6084/m9.figshare.19885937","doi":"https://doi.org/10.6084/m9.figshare.19885937","is_oa":true,"landing_page_url":"https://doi.org/10.6084/m9.figshare.19885937","pdf_url":null,"source":{"id":"https://openalex.org/S4377196282","display_name":"Figshare","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I4210132348","host_organization_name":"Figshare (United Kingdom)","host_organization_lineage":["https://openalex.org/I4210132348"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":null,"is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":"Dataset"},{"id":"doi:10.6084/m9.figshare.19885937.v1","doi":"https://doi.org/10.6084/m9.figshare.19885937.v1","is_oa":true,"landing_page_url":"https://doi.org/10.6084/m9.figshare.19885937.v1","pdf_url":null,"source":{"id":"https://openalex.org/S4377196282","display_name":"Figshare","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I4210132348","host_organization_name":"Figshare (United Kingdom)","host_organization_lineage":["https://openalex.org/I4210132348"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":null,"is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":"Dataset"},{"id":"doi:10.6084/m9.figshare.19885937.v2","doi":"https://doi.org/10.6084/m9.figshare.19885937.v2","is_oa":true,"landing_page_url":"https://doi.org/10.6084/m9.figshare.19885937.v2","pdf_url":null,"source":{"id":"https://openalex.org/S4377196282","display_name":"Figshare","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I4210132348","host_organization_name":"Figshare (United Kingdom)","host_organization_lineage":["https://openalex.org/I4210132348"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":null,"is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":"Dataset"}],"best_oa_location":{"id":"pmh:oai:figshare.com:article/19885937","doi":null,"is_oa":true,"landing_page_url":"https://figshare.com/articles/dataset/Healthcare_resource_utilization_and_costs_among_patients_with_psoriasis_treated_with_ixekizumab_or_adalimumab_over_two_years_of_follow-up_in_real-world_settings/19885937","pdf_url":null,"source":{"id":"https://openalex.org/S4377196282","display_name":"Figshare","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I4210132348","host_organization_name":"Figshare (United Kingdom)","host_organization_lineage":["https://openalex.org/I4210132348"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"","raw_type":"Dataset"},"sustainable_development_goals":[{"score":0.9763000011444092,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2990018312","https://openalex.org/W4297229131","https://openalex.org/W4321851665","https://openalex.org/W2955265488","https://openalex.org/W6901834638","https://openalex.org/W2541033253","https://openalex.org/W4223599202","https://openalex.org/W3201047607","https://openalex.org/W7202394018","https://openalex.org/W4238821550"],"abstract_inverted_index":{"To":[0],"compare":[1],"long-term":[2],"healthcare":[3],"resource":[4],"utilization":[5],"(HCRU)":[6],"and":[7,81,84,112,125,134,197,205,278],"costs":[8,85,120,171,244,273],"among":[9],"patients":[10,27],"who":[11,30],"initiated":[12],"ixekizumab":[13],"(IXE)":[14],"or":[15,36],"adalimumab":[16],"(ADA)":[17],"for":[18,34,64,88,110,123],"treatment":[19,72,78,266],"of":[20,61,67,71,91,102,156],"psoriasis":[21,29],"in":[22,175,213,231,238,248],"the":[23,59,226],"United":[24],"States.":[25],"Adult":[26],"with":[28,269],"had":[31,140],"\u22651":[32],"claim":[33,63,232],"IXE":[35,133,138,176,239,249],"ADA":[37,136,168,178,241,251],"were":[38,86,94,105,121,172,245,261,274],"identified":[39],"from":[40],"IBM":[41],"MarketScan":[42],"claims":[43,190],"databases":[44],"prior":[45],"to":[46,76,193,207,223],"COVID-19":[47],"pandemic":[48],"(01":[49],"March":[50],"2016":[51],"\u2013":[52],"31":[53],"October":[54],"2019).":[55],"Index":[56,118,271],"date":[57,60],"was":[58,74,236],"first":[62],"index":[65],"drug":[66,119,272],"interest.":[68],"Inverse":[69],"probability":[70],"weighting":[73],"employed":[75],"balance":[77],"cohorts.":[79],"All-cause":[80,234],"psoriasis-related":[82,103],"HCRU":[83,235],"examined":[87],"24":[89,257],"months":[90],"follow-up.":[92],"Costs":[93,101],"reported":[95],"as":[96],"per":[97,99,158],"patient":[98,202],"month.":[100],"biologics":[104],"adjusted":[106,122],"using":[107],"published":[108],"Institute":[109],"Clinical":[111],"Economic":[113],"Review":[114],"(ICER)":[115],"discount":[116,127,219],"factors.":[117],"adherence":[124,267,279],"ICER":[126,218,254,277],"rates.":[128],"The":[129],"analyses":[130],"included":[131],"407":[132],"2,702":[135],"users.":[137,169,242],"users":[139,179,252],"significantly":[141,173],"higher":[142,174,237,247,265],"inpatient":[143],"admission":[144,159],"rate":[145],"(all-cause":[146,180],"HCRU:14.9%":[147],"vs.":[148,162,183],"11.0%;":[149],"P":[150,164,185],"=":[151,165],"0.012),":[152],"greater":[153],"mean":[154],"length":[155],"stay":[157],"(days,":[160],"6.6":[161],"4.1;":[163],"0.004)":[166],"than":[167,177,240,250],"ICER-adjusted":[170],"costs:":[181],"$4132":[182],"$3610;":[184],"Study":[186],"relied":[187],"on":[188],"administrative":[189],"data,":[191],"subjected":[192],"data":[194,198],"coding":[195],"limitations":[196],"entry":[199],"errors.":[200],"Rebates,":[201],"assistance":[203],"programs":[204],"commission":[206],"wholesalers":[208],"are":[209],"not":[210],"always":[211],"captured":[212],"claims.":[214],"Adjustment":[215],"made":[216],"by":[217,264],"factors":[220],"may":[221],"lead":[222],"double-discounting":[224],"if":[225],"discounts,":[227],"have":[228],"been":[229],"applied":[230],"payments.":[233],"Healthcare":[243],"also":[246],"after":[253,276],"adjustment,":[255],"over":[256],"months.":[258],"Cost":[259],"differences":[260],"largely":[262],"driven":[263],"associated":[268],"IXE.":[270],"comparable":[275],"adjustments.":[280]},"counts_by_year":[],"updated_date":"2026-11-08T12:12:28.789561","created_date":"2024-04-08T00:00:00"}